Abstract: An extract of Citrus depressa, preferably a water and/or organic solvent extract of a fruit of leaf of Citrus depressa, a supercritical extract of a fruit of leaf of Citrus depressa, or a subcritical extract of a fruit of leaf of Citrus depressa, which comprise 0.3 mass % or more of a polymethoxyflavonoid more than in terms of solid matter, for example, an extract of Citrus depressa comprising 0.2 mass % or more of nobiletin and/or 0.1 mass % or more of tangeretin in terms of solid matter, or a polymethoxyflavonoid such as nobiletin or tangeretin is used as an active ingredient of an IGF-1 production-promoting agent.

Abstract: An extract of Citrus depressa, preferably an organic solvent extract of a fruit and/or leaf of Citrus depressa, a supercritical extract of a fruit and/or leaf of Citrus depressa, or a subcritical extract of a fruit and/or leaf of Citrus depressa, containing 0.3 mass % or more of a polymethoxyflavonoid in terms of solid matter, for example, 0.2 mass % or more of nobiletin and/or 0.1 mass % or more of tangeretin in terms of solid matter, or a polymethoxyflavonoid, such as nobiletin and tangeretin, is used as an active ingredient of a muscle atrophy inhibitor.

Abstract: An extract of Citrus depressa, preferably an organic solvent extract of a fruit and/or leaf of Citrus depressa, a supercritical extract of a fruit and/or leaf of Citrus depressa, or a subcritical extract of a fruit and/or leaf of Citrus depressa, containing 0.3 mass % or more of a polymethoxyflavonoid in terms of solid matter, for example, 0.2 mass % or more of nobiletin and/or 0.1 mass % or more of tangeretin in terms of solid matter, or a polymethoxyflavonoid, such as nobiletin and tangeretin, is used as an active ingredient of a muscle atrophy inhibitor.

Abstract: An extract of Citrus depressa, preferably a water and/or organic solvent extract of a fruit of leaf of Citrus depressa, a supercritical extract of a fruit of leaf of Citrus depressa, or a subcritical extract of a fruit of leaf of Citrus depressa, which comprise 0.3 mass % or more of a polymethoxyflavonoid more than in terms of solid matter, for example, an extract of Citrus depressa comprising 0.2 mass % or more of nobiletin and/or 0.1 mass % or more of tangeretin in terms of solid matter, or a polymethoxyflavonoid such as nobiletin or tangeretin is used as an active ingredient of an IGF-1 production-promoting agent.

Abstract: An extract of Citrus depressa, preferably an organic solvent extract of a fruit and/or leaf of Citrus depressa, a supercritical extract of a fruit and/or leaf of Citrus depressa, or a subcritical extract of a fruit and/or leaf of Citrus depressa, containing 0.3 mass % or more of a polymethoxyflavonoid in terms of solid matter, for example, 0.2 mass % or more of nobiletin and/or 0.1 mass % or more of tangeretin in terms of solid matter, or a polymethoxyflavonoid, such as nobiletin and tangeretin, is used as an active ingredient of a muscle atrophy inhibitor.

Abstract: A Lactobacillus bifidus growth promoting composition which significantly grows lactobacillus bifidus and does not produce any side effect such as diarrhea, and a blend comprising the above composition and other edible ingredients, and the composition comprises at least one oligosaccharide selected among lactulose, fructo-oligosaccharide, and galacto-oligosaccharide, and raffinose as the active ingredients.

Abstract: A Lactobacillus bifidus growth promoting composition which significantly grows lactobacillus bifidus and does not produce any side effect such as diarrhea, and a blend comprising the above composition and other edible ingredients, and the composition comprises at least one oligosaccharide selected among lactulose, fructo-oligosaccharide, and galacto-oligosaccharide, and raffinose as the active ingredients.